No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
IMNM Immunome
- 15.460
- -0.290-1.84%
Close May 6 16:00 ET
- 16.000
- +0.540+3.49%
Post 18:20 ET
926.72MMarket Cap-2873P/E (TTM)
16.180High15.120Low492.43KVolume15.750Open15.750Pre Close7.61MTurnover1.11%Turnover RatioLossP/E (Static)59.94MShares30.95852wk High7.73P/B684.63MFloat Cap4.50052wk Low--Dividend TTM44.28MShs Float63.780Historical High--Div YieldTTM6.73%Amplitude2.090Historical Low15.448Avg Price1Lot Size
Post-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Immunome Appoints Kinney Horn as Chief Business Officer
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointmen
Immunome Announces Executive Shift, Welcomes New Accounting Officer
Immunome Initiated at Overweight by JP Morgan
Immunome Initiated at Overweight by JP Morgan
JPMorgan Starts Immunome With Overweight Rating, $24 Price Target
JPMorgan Starts Immunome With Overweight Rating, $24 Price Target.
Analysts Offer Insights on Healthcare Companies: Immunome (IMNM), Dyne Therapeutics (DYN) and Dexcom (DXCM)
Immunome Appoints Sandra Swain and Revises Audit Committee
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg